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Cortical branched actin determines cell cycle progression
Nicolas Molinie1, Svetlana N. Rubtsova1,2, Artem Fokin1, Sai P. Visweshwaran 1, Nathalie Rocques1, Anna Polesskaya1,
Anne Schnitzler3, Sophie Vacher3, Evgeny V. Denisov4,5, Lubov A. Tashireva4, Vladimir M. Perelmuter4, Nadezhda V. Cherdyntseva4,5,
Ivan Bièche3 and Alexis M. Gautreau1,6
The actin cytoskeleton generates and senses forces. Here we report that branched actin networks from the cell cortex depend on
ARPC1B-containing Arp2/3 complexes and that they are speciﬁcally monitored by type I coronins to control cell cycle progression in
mammary epithelial cells. Cortical ARPC1B-dependent branched actin networks are regulated by the RAC1/WAVE/ARPIN pathway
and drive lamellipodial protrusions. Accordingly, we uncover that the duration of the G1 phase scales with migration persistence in
single migrating cells. Moreover, cortical branched actin more generally determines S-phase entry by integrating soluble stimuli
such as growth factors and mechanotransduction signals, ensuing from substratum rigidity or stretching of epithelial monolayers.
Many tumour cells lose this dependence for cortical branched actin. But the RAC1-transformed tumour cells stop cycling upon
Arp2/3 inhibition. Among all genes encoding Arp2/3 subunits, ARPC1B overexpression in tumours is associated with the poorest
metastasis-free survival in breast cancer patients. Arp2/3 speciﬁcity may thus provide diagnostic and therapeutic opportunities in
cancer.
Cell Research (2019) 0:1–14; https://doi.org/10.1038/s41422-019-0160-9
INTRODUCTION
Actin polymerises either in a linear or in a branched manner.
Whereas formins polymerise linear actin, the Arp2/3 complex
polymerises branched actin in the cell. Branched actin networks
develop a pushing force, which promotes protrusion of the
plasma membrane or ﬁssion of intracellular membranes.1 The
Arp2/3 complex is activated by Nucleation Promoting Factors
(NPFs) and a pre-existing actin ﬁlament, onto which the Arp2/3
complex must land to induce the growth of a “daughter ﬁlament”
from the side of the “mother ﬁlament”.2 The Arp2/3 complex itself
thus creates the branching junction of two actin ﬁlaments. The
Arp2/3 complex is activated at different subcellular locations by
various NPFs.1 For example, the WAVE complex is critical for the
formation of lamellipodia, whereas the WASH complex is critical
for the scission of transport intermediates from endosomes.
During cell migration, the leading edge protrudes as an
adherent structure called a lamellipodium. At the lamellipodium
edge, Arp2/3 complexes are activated by WAVE complexes, whose
recruitment and activation depend on the small GTPase RAC1.3
RAC1 signalling also activates the Arp2/3 inhibitory protein ARPIN,
which terminates the protrusion.4 This antagonistic Arp2/3
regulation by RAC1 thus regulates the protrusion lifetime. With a
long lifetime, the protrusion develops into a lamellipodium that
mediates persistent migration;5 with a short lifetime, branched
actin contributes to the actin cortex and to limited membrane
ﬂuctuations.6,7
When investigating what determines the lifetime of protrusions,
we revisited well-known inducers of lamellipodia. Starved cells are
immobile and arrested in the cell cycle. When stimulated by
growth factors, they develop lamellipodia, and resume cell cycle
progression (Supplementary information, Fig. S1a). Conﬂuent cells
are also immobile and arrested in the cell cycle. A wound in the
monolayer induces cells of the periphery to develop lamellipodia
and to resume cell cycle progression (Supplementary information,
Fig. S1b). Both migration and proliferation contribute to wound
healing. These examples illustrate a possible coupling between
migration and cell cycle progression and raise the question of
whether actin polymerisation is involved in the regulation of cell
cycle progression.
RESULTS
Cortical branched actin controls cell cycle progression
Using the human MCF10A breast immortalised cell line and EdU
incorporation during S phase as a read-out for cell cycle
progression, we found that two drugs, Cytochalasin D and
Latrunculin A, that block actin polymerisation, stopped the cell
cycle in a dose-dependent manner (Supplementary information,
Fig. S2), as reported decades ago in mouse embryonic ﬁbroblasts.8
Strikingly, the cell cycle block was also obtained with two
structurally unrelated Arp2/3 inhibitors,9 but not with the formin
inhibitor SMIFH2 (Fig. 1a; Supplementary information, Fig. S2).
Arp2/3 inhibition arrested cells in G1 (Supplementary Information,
Fig. S3). The G1 block was reversed upon drug washout indicating
that the block of cell proliferation was not due to apoptosis, nor
senescence. Arp2/3 inhibition did not impair cytokinesis during
mitosis of MCF10A cells (Supplementary Information, Fig. S3e,
Movie S1). Primary mammary epithelial cells also blocked cell cycle
progression in response to Arp2/3 inhibition (Fig. 1a), indicating
that this effect was not associated with the immortalisation of the
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MCF10A cell line. Furthermore, RNAi-mediated depletion of the
Arp2/3 complex, using esiRNAs (see Material and Methods),
blocked cell cycle progression, just like drug-mediated inhibition
(Fig. 1b). All together, these results strongly suggest that branched
actin structures generated by the Arp2/3 complex are required for
the G1-S transition of the cell cycle.
To look for a possible speciﬁcity in the branched actin structures
playing this role, we inactivated each known NPF by targeting the
BRK1 subunit of the WAVE complex, the CCDC53 subunit of the
WASH complex, the ubiquitous N-WASP and the two paralogous
WHAMM and JMY proteins.1 Only WAVE complex depletion led to
a severe cell cycle arrest, similar to Arp2/3 depletion (Fig. 1c;
Supplementary information, Figs. S1c, S4). Since the activity of
WAVE depends on the RAC1 GTPase, the master inducer of
lamellipodia, we inhibited RAC1 using the NSC23766 compound
and this treatment indeed prevented S-phase entry (Fig. 1d). To
conﬁrm the role of RAC1, we used a genome-edited MCF10A cell
line, where one RAC1 allele encodes the constitutively active,
GTPase-defective, Q61L mutant. Importantly, cell cycle progres-
sion of RAC1 Q61L-expressing cells was potentiated in this case,
since a higher dose of the Arp2/3 drug was required to achieve
the same level of inhibition in these cells as compared to wild type
cells. Depletion of ARPIN, which antagonizes WAVE, also
potentiated cell cycle progression (Fig. 1e). These results establish
that branched actin networks polymerised by the RAC1-WAVE
pathway, and antagonised by ARPIN, deliver the essential signal
for cell cycle progression. But how does the cell discriminate
cortical branched actin networks from the other ones involved in
intracellular trafﬁcking?
Speciﬁc sensing of cortical branched actin
To identify the protein sensing cortical branched actin, we
screened all molecules reported to recognise the Arp2/3 complex
in the context of the actin branch, namely cortactin, GMFs and
type I coronins, which all regulate the stability of the branched
junction10,11 (Fig. 2a). Only CORO1B was strictly required for cells
to cycle. CORO1B decorates lamellipodia (Fig. 2b), as previously
reported,12 but was absent from the endosomal domain that
polymerises branched actin networks,13–15 whereas both actin
structures were stained by Cortactin (Supplementary information,
Fig. 1 Delineation of the actin structure that controls cell cycle progression. a The CK-666 drug that blocks Arp2/3 activation, but not the
inactive control, CK-689, prevents cell cycle progression of primary mammary epithelial cells and of mammary immortalised MCF10A cells,
which are then used throughout the work except when otherwise indicated. Drug treatments are for 16 h. The number of cells in S phase is
monitored by the incorporation of the thymidine analogue, EdU, provided to the cells for 1 h. b Depletion of the Arp2/3 complex, through two
of its subunits, ARPC2 and ARP3, blocks S-phase entry. c Depletion of all known NPFs, the Arp2/3 activators. The WAVE complex targeted
through its subunit BRK1, but not the WASH complex targeted through its subunit CCDC53, nor the others, is critical for cell cycle progression.
d The drug NSC23766 that impairs RAC1 activation impedes S-phase entry in a dose-dependent manner; genome-edited MCF10A cells where
one RAC1 allele encodes the constitutively active Q61L form are less sensitive to Arp2/3 inhibition than WT cells. e Cells depleted of the Arp2/3
inhibitory protein, ARPIN, are also less sensitive to Arp2/3 inhibition than control cells. Data are mean ± s.e.m of ﬁve technical repeats; one
experiment representative of two biological repeats is displayed; Mann–Whitney test at 200 µM of drug for a, d and e, one-way ANOVA
followed by Dunnett’s post-Hoc test for b and c
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Fig. S5). CORO1B enrichment at the cortex depended on Arp2/3
activity, being decreased by Arp2/3 inhibition and increased by
ARPIN depletion (Fig. 2c). CORO1B thus fulﬁls the required
properties for a speciﬁc sensor of cortical branched actin. The
next question was what speciﬁc cue CORO1B might be sensing at
the cortex.
Type I coronins were reported to partially destabilise actin
branches,10 depending on the precise composition of paralogous
subunits in the Arp2/3 complex.16 We thus compared the two
ARPC1 paralogous subunits with the single ARPC2 subunit by
siRNA-mediated depletion. When ARPC2 was depleted, both
ARPC1A and ARPC1B were down-regulated, whereas ARPC2 levels
were only modestly affected when either one of the two
ARPC1 subunits was depleted (Fig. 3a). This result suggests that
ARPC1A- and ARPC1B-containing Arp2/3 complexes co-exist in
MCF10A cells. Depletion of ARPC1B, but not of ARPC1A, affected
the formation of cortical branched actin networks and lamellipo-
dia, similar to the result of single ARPC2 subunit depletion (Fig. 3b,
c; Supplementary information, Fig. S6). In contrast, depletion of
ARPC1A, but not of ARPC1B, impaired the formation of branched
actin networks at the surface of endosomes (Supplementary
information, Fig. S5). These differential requirements of ARPC1A-
and ARPC1B-containing complexes were also obvious in migration
persistence, which was strongly decreased in ARPC1B-depleted
cells (Fig. 3d; Supplementary information, Movie S2). Some level of
competition between the two types of Arp2/3 complexes,
however, must exist, since migration persistence was increased
in ARPC1A-depleted cells. Strikingly, cell cycle progression
mirrored migration persistence: S-phase entry was decreased in
ARPC1B- and ARPC2-depleted cells and increased in ARPC1A-
depleted cells (Fig. 3e). We then examined the cellular localization
of ARPC1A and ARPC1B by immunoﬂuorescence using two
speciﬁc antibodies from different species that allowed simulta-
neous labelling in the same cells (Supplementary information,
Fig. S7). In line with their differential roles, ARPC1B was enriched at
the lamellipodium, whereas ARPC1A was mostly labelling dotty
internal structures (Fig. 3f).
To conﬁrm these localisations and to complement loss-of-
function by gain-of-function experiments, we isolated stable
MCF10A lines stably expressing the two GFP-ARPC1 fusion
proteins (Fig. 3g). GFP-ARPC1B replaced endogenous ARPC1B
and its opposite paralog, ARPC1A. GFP-ARPC1A displayed a similar
behavior, albeit less strongly. Indeed, overexpression of ARPC1A is
less prominent than that of ARPC1B, as judged by the
corresponding increase in ARPC2 levels, which likely reﬂect total
Arp2/3 levels. Consistent with depletion experiments, GFP-ARPC1B
was clearly enriched in lamellipodia, whereas GFP-ARPC1A did not
display an obvious cortical localisation (Fig. 3h). Moreover, GFP-
ARPC1B overexpression increased the number of cells displaying
lamellipodia (Fig. 3i). In contrast, at the surface of endosomes,
GFP-ARPC1A, but not GFP-ARPC1B, colocalised with the retromer
that recruits the WASH complex (Supplementary information,
Fig. S5).15 Consistently, ARPC1B overexpression strongly increases
migration persistence, whereas ARPC1A expression decreases it
(Fig. 3j; Supplementary information, Movie S3). EdU incorporation
was strongly enhanced by the overexpression of ARPC1B and
decreased by the expression of ARPC1A (Fig. 3k). In fact, in all
genetic perturbations examined, cell cycle progression appeared
coupled to lamellipodium formation and migration persistence
(Supplementary information, Fig. S8).
To visualise cell cycle progression in live cells, we used the
FUCCI system17 and established a MCF10A cell line, which
expresses two different ﬂuorescent markers for G1 and S-G2,
respectively (Fig. 4a). We tracked individual cells over time to
obtain simultaneously cell trajectories and cell cycle phases.
When cells were starved of growth factors (GF) in a medium
without serum, nor EGF, migration persistence dropped and the
duration of the G1 phase increased up to 10 h (Fig. 4b). In
contrast, when cells were stimulated with the optimal concen-
tration of GF (5% GF, i.e., 5% serum and 20 ng/mL EGF),
migration became persistent and G1 lasted only about 5 h.
These results suggest an antagonism between G1 duration and
migration persistence. When cells were stimulated with 1% GF,
distributions of both persistence and G1 duration became
greatly scattered in the population. Some cells migrated
persistently and appeared to have relatively short G1, whereas
less persistent cells appeared to have longer G1 phases (Fig. 4c,
Supplementary information, Movie S4). When G1 duration of
individual cells was plotted against their migration persistence,
a striking linear correlation was revealed. G1 duration was
strongly inversely correlated to migration persistence (r=−0.88,
P < 10−4; Fig. 4d). Such a correlation with migration persistence
was not found for the duration of S and G2 phases
(Supplementary information, Fig. S9). We then depleted ARPC1A
and ARPC1B in the FUCCI cell line and observed the same
scaling relationship, with ARPC1A-depleted cells populating the
short G1—high persistence part of the regression line and
ARPC1B-depleted cells populating the long G1—low persistence
part (Fig. 4d). With or without genetic perturbation, migration
persistence, which reﬂects the polymerisation of cortical
branched actin, appears to determine the S-phase entry. But
how does cortical branched actin play this role?
Fig. 2 CORO1B speciﬁcally senses cortical branched actin. a RNAi screen for the proteins that control cell cycle progression among the known
proteins that recognise the Arp2/3 complex at the actin branch. CTTN encodes Cortactin, GMFB and GMFG encode the two Glial Maturation
Factors β and γ, and CORO1A, CORO1B and CORO1C encode the three type I coronins. Western blot targeting Cortactin and CORO1B validate
their depletion. b Confocal images of MCF10A expressing GFP-CORO1B stained with antibodies targeting the WAVE2 NPF and the branched
actin marker, Cortactin. Sum of radial line scans registered with respect to the cell edge of one lamellipodium (representative of 10 from
different cells). c Cortical enrichment of CORO1B depends on Arp2/3 activity. Confocal images of MCF10A expressing GFP-CORO1B. Cells were
treated with the Arp2/3 inhibitor CK-666 or depleted of ARPIN, as indicated. Data are mean ± s.e.m of ﬁve technical repeats (a, c); two
biological repeats with similar results; two-way ANOVA followed by Sidak’s test for c. Scale bar: 10 µm
Article
3
Cell Research (2019) 0:1 – 14
Integration of biochemical and biophysical signals
Cells progress into the cell cycle when they are anchored to the
extracellular matrix and stimulated by growth factors.18 To
investigate whether cortical branched actin transmits these
stimuli, we analysed potentiated cells with increased cortical
branched actin, through either RAC1 Q61L expression, ARPIN
depletion, or ARPC1B overexpression.
Growth factors (GFs) tightly regulate cell cycle progression.
MCF10A cells cycle at full speed in 5% GF and stop at 0% GF
(Fig. 5a). Potentiated cells exhibited the same tight regulation by
GFs, with background levels of cycling at 0% GF and maximum
cycling at 5% GF. Enhanced cycling was, however, observed at
intermediate levels of stimulation (Fig. 5a). Cell adhesion controls
cell cycle progression by mechanotransducing the rigidity of the
substrate.19 We found that more MCF10A cells cycle on rigid
substrates with 1.8 kPa stiffness than on softer substrates with 0.2
kPa stiffness (Fig. 5b). At 0.2 kPa, cells display poorly developed
lamellipodia, since substrate compliance does not allow them to
expand (Supplementary information, Movie S5). More potentiated
cells cycled compared with control cells at 0.2 kPa, but not at 1.8
kPa. These two instances show that nucleation of cortical
branched actin makes a difference upon suboptimal stimulation,
not when cell cycle progression is already fully stimulated by
maximum GF stimulation on rigid substrates.
We thus decided to examine the importance of cortical
branched actin when combining these two signals, GF and
stiffness. In control cells, the tendency of cell cycle progression
decays fast, when GF stimulation or substrate stiffness is not
optimal (Fig. 5c). In contrast, MCF10A cells with enhanced cortical
branched actin cycled about 10 times more than control cells
when both GF and rigidity are suboptimal (Fig. 5c; Supplementary
information, Fig. S10). Most importantly, cell cycle progression
scaled with the enrichment of CORO1B at the cell cortex,
measured in a median plane of cells far from potential
lamellipodia (Fig. 5d), suggesting that S-phase entry occurred
when a sufﬁciently large amount of ARPC1B containing branches
were formed at the cell cortex. The striking combined effect of GF
and substratum rigidity is likely physiological, since breast
epithelial cells naturally reside in a soft tissue where GF
stimulation is limited. But a mammary epithelial cell normally
interacts with its neighbouring cells.
We thus tested the role of cortical branched actin in density-
dependent inhibition of cell cycle progression.20 When different
number of cells were plated, MCF10A cells cycled in sparse
cultures and stopped at conﬂuence. Again, ARPIN-depleted cells
or ARPC1B-overexpressing cells kept this regulation, but cycled
more than control cells at an intermediate cell density (Fig. 6a).
Interestingly, a fully conﬂuent epithelial monolayer can resume
Fig. 3 ARPC1B-containing Arp2/3 complexes nucleate the cortical branched actin that drives migration persistence and promotes cell cycle
progression. a The single Arp2/3 subunit ARPC2 or the two paralogous subunits, ARPC1A and ARPC1B, were depleted using siRNA. The partial
down-regulation of ARPC2, upon ARPC1A or ARPC1B depletion, suggests that both ARPC1A- and ARPC1B-containing complexes co-exist in
MCF10A cells. b Depletion of Arp2/3 complexes containing ARPC1B, but not ARPC1A, impairs the formation of cortical branched actin
networks, as indicated by Cortactin staining. c Depletion of the Arp2/3 complexes that contain ARPC1B decreases the number of cells
displaying lamellipodia, whereas the depletion of complexes containing ARPC1A increases it (n > 130 cells). d Depletion of ARPC1B decreases
migration persistence of MCF10A cells, in line with its effect on lamellipodium formation; depletion of ARPC1A increases migration
persistence (n= 15 cells). e ARPC1B depletion decreases cell cycling, whereas ARPC1A depletion increases it. f Immunoﬂuorescence of
ARPC1A and ARPC1B in MCF10A cells. Endogenous ARPC1B, but not ARPC1A, localises to the lamellipodium. g Characterisation of stable
MCF10A cell lines expressing GFP-ARPC1A or GFP-ARPC1B by western blot. h GFP-ARPC1B, but not GFP-ARPC1A, localises to the
lamellipodium. i Cells overexpressing GFP-ARPC1B display more lamellipodia compared to controls (n > 110 cells). j Expression of GFP-ARPC1B
increases persistent migration, whereas the expression of GFP-ARPC1A decreases it. k ARPC1B expression increases cell cycling, whereas
ARPC1A depletion decreases it. Data are mean ± s.e.m; one experiment representative of two biological repeats is displayed, one-way ANOVA
followed by Dunnett’s post-Hoc compared to the control for c–e, i–k. Confocal microscopy; Scale bar: 5 µm
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cycling when stretched biaxially.21 This mechanotransduced
response was signiﬁcantly enhanced in MCF10A cells when
cortical branched actin was enhanced (Fig. 6b). Cortical branched
actin is, therefore, also involved in mediating density-dependent
inhibition of cell cycle progression.
Since branched actin at the cell cortex integrated the three
inputs, growth factors, cell-substratum adhesion and cell density,
we then tried to induce differentiation of the potentiated cells
with more cortical branched actin in a physiological setting. When
embedded in matrigel, single MCF10A cells proliferate and
differentiate into acini. For this long term assay, which typically
requires 3 weeks, we isolated ARPIN knockout cells using the
CRISPR-Cas9 system (Supplementary information, Fig. S11). ARPIN-
depleted cells and ARPC1B-overexpressing cells formed larger
Fig. 4 Correlation of G1 phase duration with migration persistence in single cells. a A FUCCI reporter cell line was obtained by isolating a
stable MCF10A clone expressing GFP-Geminin and Cdt1-RFP. b Individual cells were tracked during random migration in either 0, 1 or 5%
growth factors (GFs; 1% GF is 1% serum supplemented with 4 ng/mL EGF, n= 15 cells). G1 duration is the time from cytokinesis, visible in
phase contrast, to the transition from red to green seen by ﬂuorescence. Migration persistence is calculated during the G1 phase. GF triggers
persistent migration and decreases G1 duration. At 1% GF, the distributions of both persistence and G1 duration are scattered. One-way
ANOVA followed by Dunnett’s post-Hoc. c Migration and cell cycle progression in individual cells at 1% GF. The cells that migrate persistently
(with a straight trajectory) appear to have shorter G1 phases than the less persistent ones. G1 duration is indicated in yellow. Scale bar: 30 µm.
d G1 duration is inversely correlated to migration persistence during G1 (Pearson’s correlation coefﬁcient, r, and probability that this correlated
distribution arises by chance, p, n= 39 cells). ARPC1A- and ARPC1B-depleted cells display the same correlated distribution, with ARPC1A-
depleted cells exhibiting high persistence and short G1, and with ARPC1B-depleted cells exhibiting low persistence and long G1 (n= 20 cells)
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acini containing more cells (Fig. 6c). These acini were composed of
correctly polarised cells, as evidenced by the apical localisation of
their Golgi complexes, which face the lumen (Supplementary
information, Fig. S12). MCF10A cells expressing active RAC1
formed large 3D clusters with less well deﬁned lumen and less
polarised cells. All cell lines with enhanced cortical branched actin
thus formed 3D structures with an increased number of cells in
differentiation conditions. Since unregulated proliferation char-
acterises tumour cells, we sought to examine whether cortical
branched actin was also involved in cell transformation.
Importance for cancer
MCF10A cells are immortalised, but not transformed, breast
epithelial cells. The MCF10DCIS.com cell line is a derivative of
MCF10A transformed by oncogenic HRAS, which was, furthermore,
selected in vivo to give rise to ductal carcinoma in situ.22 When
MCF10DCIS.com cells were compared to MCF10A cells for their
ability to cycle depending on growth factors, substrate rigidity or
cell density, they behaved similar to MCF10A cells with enhanced
cortical branched actin (Supplementary information, Fig. S13a).
The morphogenesis of MCF10DCIS.com in 3D matrigel was
strongly altered. Cell clusters grew large, but never developed a
lumen (Supplementary information, Fig. S13b). Unlike parental
MCF10A cells, MCF10DCIS.com cells cycled even when the Arp2/3
complex was inhibited. We screened 9 additional human breast
cell lines and 1 human melanoma cell line for their requirement of
cortical branched actin. Strikingly, all three immortalised cell lines
stopped cycling in response to Arp2/3 inhibition, like MCF10A cells
(Fig. 7a), whereas all 6 transformed ones, i.e., the ones giving rise
to tumours upon grafting, continued to cycle upon Arp2/3
inhibition, like MCF10DCIS.com cells (Fig. 7b). Tumour cells
activate various oncogenes and inactivate various tumour
suppressor genes. We found that inactivating the tumour
suppressor gene RB1 or CDKN1A, which encodes the CDK
inhibitory protein p21WAF1/CIP1, sufﬁces to render the untrans-
formed MCF10A cell line insensitive to Arp2/3 inhibition (Fig. 7c).
Together, these results suggest that losing the requirement for
branched actin lies at the core of cell transformation.
Since RAC1, upstream of cortical branched actin, is also an
oncoprotein activated by the hotspot missense mutation P29S in
melanomas,23 we collected cell lines that speciﬁcally harboured
oncogenic forms of RAC proteins.24–26 Contrary to randomly
picked tumour cell lines, which were insensitive to Arp2/3
inhibition, all the cell lines that contained an active RAC1 protein
stopped cycling upon Arp2/3 inhibition (Fig. 8a). Importantly,
Arp2/3 inhibition blocked the clonogenic ability of these
Fig. 5 Cortical branched actin integrates mechanical signals with biochemical stimuli. a MCF10A cells expressing RAC1 Q61L or GFP-ARPC1B
or ARPIN-depleted cells normally stop cycling when deprived of growth factors and cycle at full speed upon full GF stimulation (5%). But they
exhibit enhanced cell cycle progression at intermediate levels of stimulation. b Cells were plated at the surface of ﬁbronectin-coated gels of
various stiffness. On soft substrates, control cells cycle much less than on rigid substrates. Upon RAC1 activation, ARPIN depletion or ARPC1B
overexpression, cells cycle more than controls when the substrate is soft. c A phase diagram was explored with the four values of GF
stimulation and the three values of substratum rigidity. ARPIN depletion expands the surface associated with a high level of cycling. ARPIN
depletion exerts the most important effect on cycling, when both stimuli are intermediate (int), instead of maximum (max). d Cortical
enrichment of CORO1B scales with cell cycle progression. GFP-CORO1B at the cortex was measured as in Fig. 2c (n= 15 cells). Data are mean ±
s.e.m of technical repeats; one experiment representative of two biological repeats is displayed; Mann–Whitney test for a and b, two-way
ANOVA followed by Sidak’s test for c and d. When stars are not displayed, no signiﬁcant difference was found between groups
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melanoma and mammary carcinoma cells (Fig. 8b). Oncogenic
GTPases of the RAS superfamily are particularly difﬁcult to target,
since potential GTPase inhibitors would lock them in the active
state just like oncogenic mutations. Our results suggest that RAC1-
mediated transformation can be blocked downstream at the level
of the Arp2/3 complex, in a manner similar to the block of RAS-
mediated transformation exerted by MAP kinase inhibitors.
To examine the role of speciﬁc Arp2/3 complexes, we system-
atically measured the expression of all 10 genes encoding Arp2/
3 subunits by qRT-PCR in mammary carcinomas from a retro-
spective cohort of 527 patients. We compared mRNA levels in
tumours to the ones in normal breast. In line with previous
reports,1 we found that Arp2/3 subunits were globally over-
expressed (Fig. 9a). Overexpression of 6 subunits was signiﬁcantly
associated with a poor metastasis-free survival (MFS) of patients in
both univariate and multivariate analyses, taking into account
other classical prognosis factors (Supplementary information,
Fig. S14). ARPC1B was the most overexpressed subunit-encoding
gene and most signiﬁcantly associated with a poor prognosis
(Fig. 9a). At 5 years, ARPC1B overexpression group had a survival of
57.6% MFS vs. 74.2% for the complementary group expressing
normal levels, and at 10 years, MFS dropped to 47.1% vs. 63.9%.
Fig. 6 Cortical branched actin potentiates cell cycle progression in epithelial monolayers and in acinus morphogenesis. aWhen more MCF10A
cells are plated, cells gradually stop cycling. ARPIN-depleted cells and ARPC1B expressing cells are less sensitive to the cell density-dependent
inhibition of cell cycle progression than controls, even if they eventually become fully inhibited, like control cells. b Biaxial stretching of a fully
conﬂuent monolayer of MCF10A allows cells to resume cell cycle progression. Increased cortical branched actin induced by active RAC1,
ARPIN depletion, or ARPC1B overexpression potentiates this mechanotransduced response. c Morphogenesis of acini in 3D Matrigel. Acini
were stained with DAPI (blue), phalloidin (green) and the apical Golgi marker GM130 (red). Proﬁles correspond to the sum of radial line scans
on the DAPI staining. ARPIN knockout or ARPC1B overexpression greatly increases the acinus size. Active RAC1 also increases the acinus size,
but the lumen is not as well deﬁned, because of remaining cells in the center of the structure. Confocal microscopy; Scale bar: 40 µm. Data are
mean ± s.e.m of ﬁve technical repeats (a, b) or n= 10 (c). One experiment representative of two biological repeats is displayed. Mann–Whitney
test for a and b, one-way ANOVA followed by Dunnett’s post-Hoc compared to WT for c. When stars are not displayed, no signiﬁcant
difference was found between groups
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Fig. 7 Cell transformation is generally associated with insensitivity to Arp2/3 inhibition. a Various immortalised cell lines from human breast
were treated with the Arp2/3 inhibitor, CK-666, or with the inactive control, CK-869, at the indicated concentrations. These immortalised
human breast cell lines stopped cycling in response to Arp2/3 inhibition, in a dose-dependent manner. Mouse Embryonic Fibroblasts (MEF)
behaved the same. b Various mammary carcinoma cell lines and the melanoma cell line A375M were insensitive to Arp2/3 inhibition. c siRNA
mediated inactivation of the tumour suppressor genes RB1 and CDKN1A, which encodes the CDK inhibitory protein p21WAF1/CIP1, prevents the
cell cycle arrest due to Arp2/3 inhibition. A similar effect is seen in MCF10A cells knock-out for CDKN1A,49 and mouse embryonic ﬁbroblasts
knock-out for all three genes encoding retinoblastoma proteins.50 Data are mean ± s.e.m of ﬁve technical repeats (a–c). One experiment
representative of 2 biological repeats is displayed, Mann–Whitney test at 200 µM of drug for a–c (middle and right), twoway ANOVA followed
by Sidak’s test for c (left). For b and c, no signiﬁcant difference between groups was found
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ARPC1B expression was also related to the Scarff-Bloom-
Richardson grade of mammary carcinomas (Supplementary
information, Table S1), since 19.9% of grade III patients over-
expressed ARPC1B, compared to 8.3% for grade II and only 3.3%
for grade I. In contrast, the limited overexpression of the
paralogous ARPC1A gene had no value for the prognosis. We
veriﬁed by immunohistochemistry that carcinoma cells express
the ARPC1B protein (Supplementary information, Fig. S15). Protein
extracts were prepared from 13 breast tumours and adjacent
healthy tissue. ARPC1B, but not ARPC1A, was overexpressed in a
majority of tumours (Fig. 9b). ARPC1B overexpression was
associated with ARPC2 overexpression. Together, these results
suggest that ARPC1B-containing Arp2/3 complexes are more
abundant in mammary carcinomas than in normal tissues and that
the enhanced polymerisation of cortical branched actin they
provide contributes to breast cancer development.
DISCUSSION
Our work delineates the speciﬁcity of the branched actin networks
that transduce cell cycle progression. Only the cortical branched
actin networks that are speciﬁcally nucleated by the Arp2/3
complexes that contain the ARPC1B paralog play this signaling
role. This is in contrast with the previously reported centrosomal
role of ARPC1B, which is Arp2/3 independent.27 Cortical branched
actin networks are activated by the WAVE complex—and
Fig. 8 Cancer cell lines transformed by oncogenic RAC1 are sensitive to Arp2/3 inhibition. a RAC1 is an oncogene, which is frequently mutated
in melanomas. Four melanoma cell lines transformed by the oncogenic P29S RAC1, mammary carcinoma cell lines, MDA-MB-157 and
HCC1143, which carries an equivalent mutation on the RAC2 gene, and the osteosarcoma cell line, HT1080, which also expresses an active
version of RAC1, are all sensitive to Arp2/3 inhibition, unlike the usual tumour cell lines. Data are mean ± s.e.m of 5 technical repeats; one
experiment representative of 2 biological repeats is displayed. Mann–Whitney test at 200 µM of drug. b The clonogenic growth of melanoma
or mammary carcinoma cell lines transformed by RAC proteins is blocked upon Arp2/3 inhibition (two biological repeats)
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antagonised by ARPIN—downstream of RAC1 (Fig. 10). They are
speciﬁcally sensed by CORO1B at the cortex, because type I
coronins debranch ARPC1A-dependent actin networks, but stably
decorate ARPC1B-containing actin branches, which are immune to
debranching.16 In optimal conditions, cells stop cycling when
branched actin is depleted; in suboptimal conditions, formation of
more cortical branched actin by RAC1 activation, ARPIN depletion
or ARPC1B overexpression, potentiates cell cycle progression.
We showed that cortical branched actin is the prime integrator
of the various inputs that control the G1/S transition. These inputs
include both soluble stimuli, such as growth factors, and
mechanotransduced cues from cell adhesions. These signals were
long known to synergetically control cell cycle progression,
despite that the point of integration was not clear.18 Similarly,
while the actin cytoskeleton, which generates forces, had long
been hypothesized to play a role in sensing forces, the elusive
forces being sensed have only recently been ascribed to the
membrane tension of epithelial cells and to the lamellipodial
protrusive activity of single cells.28,29 Indeed, branched actin
networks were found to respond to mechanical load by becoming
denser in vitro,30 and lamellipodial actin was also found to
become denser when membrane tension was increased.31 In this
work, we examined the role of various possible actin structures,
linear and branched, nucleated by various NPFs, and our data
converged on cortical branched actin in line with previous results.
Even if the RAC1-WAVE-Arp2/3 pathway is best known for
regulating cell migration, the role of cortical branched actin in
transducing cell cycle progression extends beyond the lamellipo-
dial cytoskeleton. The striking anticorrelation between migration
persistence and G1 duration only applies to single cells. In
epithelial cells, cortical branched actin is well established to play
an essential role in the formation of cell-cell junctions.32,33 In fact,
the RAC1-WAVE-Arp2/3 pathway regulates actin polymerisation all
around the cell cortex,6,7 and the lamellipodium is just a local and
transient ampliﬁcation of the phenomenon due to positive
feedback.5 This explains why cortical enrichment of CORO1B in
a medial plane of the cell, far from lamellipodia, mirrored cell cycle
progression, when growth factor stimulation and substratum
rigidity were systematically varied.
Tumour cells are cells that proliferate when they should not. In
our work focused on mammary epithelial cells, we found that
most tumour cells do not depend on the amount of cortical
branched actin to make the decision of S-phase entry. In fact, we
were able to render cells insensitive to Arp2/3 inhibition, just by
removing a tumour suppressor gene controlling the G1-S
transition, such as RB1 or CDKN1A. There are probably many
other ways to escape the control exerted by cortical branched
actin and the dissection of the downstream signaling pathway
that impinges onto the cell cycle machinery is an important task
for future studies. However, we reasoned that cells transformed by
upstream oncogenes, like RAC1, would still require cortical
branched actin. This idea was experimentally validated in all cell
lines expressing oncogenic forms of RAC1. This result is potentially
important, as RAC1 oncogenic mutations occur in 5 to 10% of
melanoma patients.34,35 No targeted therapy is currently available
for these patients. Arp2/3 inhibition is thus a potential way to
prevent their proliferation and dissemination.
The Arp2/3 complex is overexpressed in many cancers.1 In the
case of breast cancer, the overexpression of the Arp2/3 complex,
of the WAVE complex, or down-regulation of ARPIN expression
was associated with poor survival.36–38 Given the paralogous
speciﬁcity of Arp2/3 complexes transducing cell cycle progression,
Fig. 9 Overexpression of the Arp2/3 complex is associated with a poor prognosis in breast cancer. a In a retrospective cohort of 527 breast
cancer patients, expression of genes encoding Arp2/3 subunits was measured by qRT-PCR in tumours and healthy tissue. Arp2/3-encoding
genes are often overexpressed in mammary carcinomas compared to normal breast. Overexpressions are signiﬁcantly associated with poor
metastasis-free survival (MFS) in 6 genes out of 10 in both uni- and multivariate analyses. Importantly, ARPC1B is the most frequently
overexpressed subunit and most signiﬁcantly associated with poor MFS (Kaplan–Meier survival curve, cut-off at 5). In contrast, the ARPC1A
paralogue, is not associated with patient prognosis. b Protein expression in mammary carcinomas and normal adjacent tissues was compared
by western blot. Overexpression of ARPC1B, but not of ARPC1A, detected in tumours of 11 out of 13 patients, is associated with an
overexpression of ARPC2, suggesting that these tumours display elevated levels of Arp2/3 complexes containing ARPC1B. two-way ANOVA
followed by Sidak’s test
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we systematically analysed the deregulation at play in the
expression of all Arp2/3 complex subunits in a large cohort of
breast cancer patients. ARPC1B was the most overexpressed
subunit and the most associated with poor metastasis-free
survival, in line with our in vitro results. The multivariate analysis
established that ARPC1B levels have a strong prognostic power in
isolation, independently from known clinical pathophysiological
parameters associated with metastasis-free survival. In addition to
a prognostic role, the speciﬁcity for ARPC1B-containing Arp2/3
complex uncovered here might provide the basis for future
development of small molecule inhibitors, which would speciﬁ-
cally target the molecular machinery mediating proliferation and
dissemination of tumour cells.
MATERIAL AND METHODS
Cells and drugs
MCF10A, MCF10DCIS.com, MCF10–2A, 184B5 were grown in
DMEM/F12 medium supplemented with 5% horse serum, 20 ng/
mL epidermal growth factor, 10 μg/mL insulin, 500 ng/mL hydro-
cortisone, and 100 ng/mL cholera toxin. Mouse embryonic
ﬁbroblasts, MCF7, hs578T, BC227 and HT1080 were grown in
DMEM with 10% FBS. MDA-MB-231, MDA-MB-157 and MDA-MB-
468 were grown in Leibovitz’s L-15 medium with 10% FBS. hTERT-
HME1, BT549, WM1960, A375M, 83 T, 104 T, IGR1 and HCC1143
were grown in RPMI supplemented with 10% FBS. Medium and
supplements were from Sigma. Cells were incubated at 37 °C in
5% CO2 except cells cultured in Leibovitz’s L-15 medium, which
were grown without CO2. Primary Mammary Epithelial cells were
from Lonza and cultivated in the provided medium. MCF10A RAC1
Q61L/WT were obtained from Horizon Discovery Ltd. (Cambridge,
UK). All cell lines derived from human breast were from the
collection of breast cell lines organised by Thierry Dubois (Institut
Curie, Paris), A375M, WM1960, IGR1 were from Lionel Larue
(Institut Curie, Orsay), 83 T, 104 T were from Yardena Samuels (The
Weizmann Institute of Science, Rehovot), MEF triple knockout for
Rb were from Julien Sage (Stanford University of Medicine),
MCF10A p21−/− were from Ben Ho Park (Johns Hopkins School of
Medicine, Baltimore). All cells and stable clones were routinely
tested for mycoplasma and found to be negative.
CK-666, CK-689, CK-869, Cytochalasin D, Latrunculin A, and
NSC23766 were purchased from Merck, SMIFH2 and Aphidicolin
from Sigma. For the clonogenicity assay, medium was replaced
with fresh medium containing CK-666 every three days.
Plasmids, siRNAs, gRNA and transfections
Stable MCF10A cells expressing FUCCI reporters were obtained by
sequentially transfecting MCF10A cells, with the ES-FUCCI plasmid
(Addgene #6254)39 to express mCherry-Cdt130–120 and with the
home-made plasmid MXS AAVS1L SA2A Puro bGHpA EF1Flag GFP
Geminin Sv40pA AAVS1R to express GFP-Geminin1–110 using
Lipofectamine 3000 (Thermo Fisher Scientiﬁc). Stable MCF10A
expressing GFP-CORO1B, GFP-ARPC1A or GFP-ARPC1B were
obtained by transfecting MCF10A cells with the plasmid described
above. To obtain stable integration of the MXS plasmid at the
AAVS1 site, cells were cotransfected with two TALEN plasmids
inducing DNA double strand breaks at the AAVS1 locus (Addgene
#59025 and 59026).40 Cells were selected with 1 μg/mL puromy-
cine and/or 100 μg/mL hygromycine (Invivogen) and pooled.
The MCF10A Arpin knockout cell line, clone #12, was generated
with CRISPR/Cas9 system. The targeting sequence GAGAACT-
GATCGATGTATCT was used to induce the double strand break.
Cells were transfected with crRNA:trackRNA duplex and the
puriﬁed Cas9 protein by Lipofectamine CRISPRMAX™ Cas9
Transfection Reagent (Thermoﬁsher Scientiﬁc). The next day, cells
were subjected to dilution at 0.8 cells/well in 96 well plate. Single
clones were expanded and analyzed by ARPIN western blot. A
frameshift at both alleles in positive clones was conﬁrmed by
sequencing.
To perform screens of genes involved in the cortical branched
actin pathway, genes were knocked down with esiRNAs (Sigma),
which correspond to long dsRNAs processed in vitro into a
collection of short siRNAs. Because they cover a large part of the
gene, esiRNAs are more consistently efﬁcient at depleting mRNAs
Fig. 10 Cortical branched actin controls the G1/S transition. The formation of cortical branched actin by ARPC1B-containing Arp2/3
complexes is under the control of the RAC/WAVE/ARPIN pathway. ARPC1B-containing complexes are speciﬁcally sensed by CORO1B, which
signals S-phase entry. In contrast, ARPC1A-containing complexes are critical for endosomal branched actin, but do not affect cell cycle
progression. Cortical branched actin integrates proliferation signals from soluble growth factors and mechanotransduced adhesion cues
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than individual siRNA sequences. An esiRNA corresponding to GFP
was used as a control. Only ARPIN and BRK1 were targeted by
individual siRNAs (ON-TARGETplus, Dharmacon): ARPIN#1 GUGGA
UGUAUCUCGGCACA, ARPIN#2 AUGGCAGGAAGGAGCGCUA, and
BRK1#1 GGGCUAACCGGGAGUACAUUU, BRK1#2 CGAUAUGUCUU
GUCGUUCAUU, BRK1#3 ACACUAAACGAGAAAUUGAUU, BRK1#4
GAACGGAGAAUAGAGUACAUU. In this case, the control siRNA was
the non-targeting siRNA designed by Dharmacon. MCF10A cells
were transfected using lipofectamine RNAiMax according to the
recommended reverse transfection protocol (Thermo Fisher
Scientiﬁc) and analysed 72 h later. To knock-down the Arp2/3
complex, cells were retransfected the next day with the same
quantity of esiRNA using the forward transfection protocol and
were analysed 96 h after the ﬁrst transfection.
Antibodies, western blot and immunoﬂuorescence
Home-made rabbit polyclonal antibodies were previously
described: anti-ARPIN,4 anti-CCDC53,13 anti-BRK1,41 anti-Sra1,
anti-Nap1, anti-Wave2, and anti-Abi1.42 Antibodies targeting RB1
(#9309) and p21 (#2947) were from Cell Signaling, Arp3 (#07–272),
ARPC2 (#07–227) and Cortactin (#05–180) from Millipore, CEP55
(sc-374051), VPS35 (#Sc-374372), ARPC1B (#Sc-137202 for IF of
Fig. 3f) and Coronin1B (#Sc-66838) from Santa-Cruz Biotechnol-
ogy, ARPC1A (#HPA004334), ARPC1B (#HPA004832 for WB) and
Coronin1B (#WH0057175M1) from Sigma, GM130 (#610823) and
p150Glued (#610473) from BD Biosciences, Acetyl Tubulin (C3B9-
hFc) from the TAb-IP recombinant antibodies platform of Institut
Curie, Paris, France and Tubulin (Clone E7) from Developmental
Studies Hybridoma Bank.
MCF10A cells were lysed in RIPA buffer and analysed by western
blot. SDS-PAGE was performed using NuPAGE 4–12% Bis-Tris gels
(Life Technologies). Nitrocellulose membranes were developed
with horseradish peroxidase (HRP)-coupled antibodies (Sigma)
and SuperSignal West Pico chemiluminescent substrate (Thermo
Fisher Scientiﬁc) or with alkaline phosphatase-coupled antibodies
(Promega) and NBT-BCIP as substrates (Promega).
For immunoﬂuorescence, cells were ﬁxed with 4% paraformal-
dehyde and permeabilised with 0.5 % Triton X-100. Quantiﬁcation
was performed on at least 2 different biological replicates by
measuring signal intensity with ImageJ. Endosomal branched
actin and cortical CORO1B were imaged using a confocal laser
scanning microscope (TCS SP8, Leica) equipped with an inverted
frame (Leica), a high NA oil immersion objective (HC PL APO 63×/
1.40, Leica) and a white light laser (WLL, Leica). Radial line scans
were drawn as described.4 To measure endosomal enrichment of
the protein of interest, images were thresholded using the
endosomal VPS35 signal to create a Region Of Interest (ROI), then
the mean intensity of the staining was measured in this ROI.
Endosomal enrichment was deﬁned as the ratio of the mean
intensity in the ROI divided by the mean intensity in the whole
cell. To measure CORO1B at the cortex, CellMask Deep Red Plasma
membrane Stain (Thermo Fisher Scientiﬁc) used as described43
deﬁned cell periphery. Then the integrated intensity of GFP-
CORO1B in the cortical region was divided by the integrated
intensity throughout the cell. To count the number of cells
displaying lamellipodia, a lamellipodium was deﬁned as a convex
membrane staining of Cortactin wider than 2 μm.
Cell cycle assays
For EdU assays, coverslips were coated with 10 μg/mL bovine
ﬁbronectin (Sigma) for 30min at 37 °C in PBS. 15,000 cells per cm²
were plated onto the coverslips. Drug treatment was for 16 h. EdU
(Thermo Fisher Scientiﬁc) was added to cells 1 h before ﬁxation.
Cells were processed as for immunoﬂuorescence but labelled with
the Alexa Fluor 488 Click-iT EdU Imaging Kit (Thermo Fisher
Scientiﬁc, #C10337) and DAPI (Thermo Fisher Scientiﬁc). For EdU
quantiﬁcation, the percentage of cells in S-phase was scored as
the ratio of EdU-positive nuclei / DAPI-stained nuclei in segmented
images (code available upon request). For each condition, at least
200 cells were counted. For FACS analysis, cells were trypsinised
before ﬁxation and the percentage of cells in the different phases
of the cell cycle was analysed on a Guava easyCyte system
(Millipore). β-galactosidase activity was used to stain senescent
cells after 4 days of treatment (Senescence Cells Histochemical
Staining Kit, Sigma).
For GF stimulation, cells were starved of serum and EGF for 36 h
and then stimulated for 16 h. 1% GF corresponds to 1% Horse
serum and 4 ng/mL of EGF. For the control of substrate rigidity,
polyacrylamide gels of 0.2 kPa, 1.1 kPa and 1.78 kPa were
prepared as described.44 To analyse density dependence, the
indicated number of cells was seeded on ﬁbronectin-coated
coverslips 48 h before EdU incorporation. To stretch epithelial
monolayers, 106 cells were plated on pronectin-coated ﬂexible
PDMS substrates (BioFlex culture plates) 36 h before a biaxial
stretch of 18% was applied for 16 h with the FX-5000 Tension
System (FlexCell International Corporation). For the clonogenicity
assay, cells were seeded in 6-well dishes, grown for 3 weeks, ﬁxed
and stained with crystal violet. For the acinus assay, single cells
were seeded on a 1mm thick solidiﬁed layer of matrigel (growth
factor reduced, Thermo Fisher Scientiﬁc, #CB-40230C) and grown
for 21 days in MCF10A medium with 2% horse serum and 5 ng/mL
of EGF, as previously described.45
Videomicroscopy and analysis of cell migration
Videomicroscopy was performed on an inverted Axio Observer
microscope (Zeiss) equipped with a Pecon Zeiss incubator XL
multi S1 RED LS (Heating Unit XL S, Temp module, CO2 module,
Heating Insert PS and CO2 cover), a deﬁnite focus module and a
Hamamatsu camera C10600 Orca-R2. Pictures were taken every 5
min for 24 h for migration of MCF10A and for 48 h for MCF10A-
FUCCI using the Plan-Apochromat 20×/0.80 air objective. In the
single cell migration assay, migrating cells making cell contacts for
more than 4 h during the whole tracking period were excluded
from the analysis. Random migration was analysed with ImageJ
and DiPer as described.46 Single cell persistence corresponds to
the area under the curve of the directional autocorrelation
function (without gap) plotted with DiPer.
Patient cohort for mRNA analysis
All patients (mean age 62 years, range 29–91 years) met the
following criteria: primary unilateral nonmetastatic breast carci-
noma for which complete clinical, histological and biological data
were available; no radiotherapy or chemotherapy before surgery;
and full follow-up at Institut Curie - Hospital René Huguenin. All
patients before 2007 were informed that their tumour samples
might be used for scientiﬁc purposes and had the opportunity to
decline. Since 2007, patients treated in our institution have given
their approval by signed informed consent. This study was
approved by the local ethics committee (Breast Group of René
Huguenin Hospital). Treatment (information available for 524
patients) consisted of modiﬁed radical mastectomy in 320 cases
(61%) or breast-conserving surgery plus locoregional radiotherapy
in 204 cases (39%). The patients had a physical examination and
routine chest radiotherapy every 3 months for 2 years, then
annually. Mammograms were done annually. Adjuvant therapy
was administered to 416 patients, consisting of chemotherapy
alone in 130 cases, hormone therapy alone in 178 cases and both
treatments in 108 cases. During a median follow-up of 10.5 years
(range 1 month to 36.3 years), 210 patients developed metastasis.
Sixteen specimens of adjacent normal breast tissue from breast
cancer patients and normal breast tissue from women undergoing
cosmetic breast surgery were used as sources of normal RNA.
qRT-PCR
Speciﬁc mRNAs were quantiﬁed from the cycle number (Ct value)
at which the increase in the ﬂuorescence signal started to be
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detected by the laser detector of the ABI Prism 7900 sequence
detection system (Perkin-Elmer Applied Biosystems, Foster City,
CA) as previously described.47 Speciﬁc transcripts were quantiﬁed
using the following primers: ARPC1A-U (5′-ACTCAAGGAGCACA
ACGGACAC-3′) and ARPC1A-L (5′-GGTCTGCCCCACAAGTGACA-3′)
for ARPC1A gene (PCR product of 80 bp); ARPC1B-U (5′-CAC
AAGAACAGCGTCAGCCAGAT-3′) and ARPC1B-L (5′-CTCCAAG
CTCTTCACATCCCAGATA-3′) for ARPC1B gene (PCR product of
117 bp); ARPC2-U (5′-CGTCTGACTTCCTCAAGGTGCTG-3′) and
ARPC2-L (5′-GATGAAAACGTCTTCCCCGTGAT-3′) for ARPC2 gene
(PCR product of 88 bp); ARPC3-U (5′-ACTTCAAGGCCAATG
TCTTCTTCA-3′) and ARPC3-L (5′-GCTTTTGGAATTGCACTTTTGC-3′)
for ARPC3 gene (PCR product of 125 bp); ARPC4-U (5′-
TTGCTGTGAAACAGGCTGATGAG-3′) and ARPC4-L (5′-AGAAAGCTG
ATATCATACCCCTCCA-3′) for ARPC4 gene (PCR product of 130 bp);
ARPC5-U (5′-GCAATGGCATGAAAAGGCACT-3′) and ARPC5-L (5′-
ATCCACTTCCTGCCAGACTACACA-3′) for ARPC5 gene (PCR product
of 96 bp); ARPC5L-U (5′-CATGCAGCCTTGCGGAACTCT-3′) and
ARPC5L-L (5′-CCCTGGGCTCGCTCCTTCA-3′) for ARPC5L gene (PCR
product of 65 bp); ACTR2-U (5′-AGAACGAGTTTTGAAGGGTGATG
T-3′) and ACTR2-L (5’-TAGAACTGCACCACCCAGGAAT-3′) for ACTR2
gene (PCR product of 106 bp); ACTR3-U (5′-CGGGGTATACAAAAC
TAGGATATGCT-3′) and ACTR3-L (5’-CATCACCCTCCTTTGAGCTTG
A-3′) for ACTR3 gene (PCR product of 116 bp); ACTR3B-U (5′-
CTTGGCTACGCAGGCAACACT-3′) and ACTR3B-L (5′-ACTCCCCTCA
ACACTCTCCTTTGA-3′) for ACTR3B gene (PCR product of 110 bp);
TBP-U (5′-TGCACAGGAGCCAAGAGTGAA-3′) and TBP-L (5′-CACATC
ACAGCTCCCCACCA-3′) for the TBP gene (PCR product of 132 bp),
which was the reference gene used for normalisation.
Patient biopsies for western blot
20 patients with invasive breast carcinoma (T1–3N0–3M0–1; grade
1–2; luminal A, B, and HER2+), between 46 and 68 years of age
(mean age: 55.2 ± 9.0), and treated in the Tomsk National Research
Medical Center between 2013 and 2015 were included. All cases
were without any preoperative therapy and underwent mastect-
omy, radical or sectoral resection. The procedures followed in this
study were in accordance with the Helsinki Declaration (1964,
amended in 1975 and 1983). This study was approved by the
institutional review board; all patients signed an informed consent
for voluntary participation.
For tissue lysis, samples were ﬁrst weighted. 3.75 μL of cold PB
buffer (100 mM HEPES, 300mM NaCl, pH 7.7) supplemented with
a mix of protease inhibitors (1 μg/mL Leupeptin, 80 μg/mL
Antipain, 1 mM PMSF, 80 μg/mL Chymostatine, 500 μg/mL Pefa-
bloc and 240 μg/mL benzamidine) were added to each mg of
tissue. Samples were then homogenised at 4 °C using a manual
piston. After homogenisation, the same volume of concentrated
RIPA buffer (100mM HEPES, 300mM NaCl, 2% NP-40, 1% Sodium
Deoxycholate, 0.2% SDS, pH 7.7) supplemented with protease
inhibitors, was added and incubated on ice for 30 min. The extract
was clariﬁed by centrifugation at maximum speed for 10min in a
tabletop centrifuge at 4 °C. Total protein concentration of the
clariﬁed lysate was determined using the BCA assay (Thermo-
scientiﬁc). Ten micrograms of samples was fractionated by SDS-
PAGE and revealed by western blotting. Signals were quantiﬁed
by densitometry using ImageJ. The ratio of speciﬁc signals to the
signal of the p150Glued loading control is calculated and
normalised to the mean ratio for normal tissue.
Biostatistics
Statistical analysis of the results was carried out with GraphPad
software. When data satisﬁed the two criteria of normality and
equal variance, parametric tests were used: t-test to compare two
groups; ANOVA for more than two, followed by Dunnett’s post-
Hoc test or by Sidak’s test. When data did not satisfy both criteria,
non-parametric tests were applied: Mann–Whitney to compare
two groups; Kruskal–Wallis for more than two. Except when
indicated otherwise, a representative experiment is plotted and
results are expressed as mean ± s.e.m of a minimum of ﬁve
technical repeats. Differences were considered signiﬁcant at
conﬁdence levels greater than 95% (P < 0.05). Four levels of
statistical signiﬁcance are distinguished: *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
In patient samples, the distribution of mRNA levels was
characterised by median values and ranges. Relationships
between mRNA levels and clinical parameters were identiﬁed
using non-parametric tests, namely the Mann–Whitney U test and
the Kruskal–Wallis test. Metastasis-free survival (MFS) was deter-
mined as the interval between initial diagnosis and detection of
the ﬁrst metastasis. Data were summarised in a receiver operating
characteristic (ROC) curve.48 The area under the curve was
calculated as a single measure to discriminate efﬁcacy. Survival
distributions were estimated by the Kaplan–Meier method, and
the signiﬁcance of differences between survival rates was
ascertained with the log-rank test. Cox’s proportional hazard
regression model was used to assess prognostic signiﬁcance in
multivariate analysis.
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